Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: August 17, 2022

Details for Patent: 4,100,274

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 4,100,274
Title: Polypeptide
Abstract:The disclosure relates to novel luliberin analogues which possess luliberin agonist activity, to processes for their manufacture and to compositions containing them. Typical of the peptides disclosed is ##STR1## in which A is D-Phe, D-Tyr(Me) or D-Ser(Bu.sup.t).
Inventor(s): Dutta; Anand Swaroop (Macclesfield, GB2), Furr; Barrington John Albert (Macclesfield, GB2), Giles; Michael Brian (Macclesfield, GB2)
Assignee: Imperial Chemical Industries Limited (London, GB2)
Application Number:05/790,003
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 4,100,274

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,100,274

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom19327/76May 11, 1976

International Family Members for US Patent 4,100,274

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365562 See Plans and Pricing
Austria 379400 See Plans and Pricing
Austria 379595 See Plans and Pricing
Austria 379596 See Plans and Pricing
Austria 379597 See Plans and Pricing
Austria 379598 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.